Open access
Oct 2026
Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma
Perioperative immunotherapy has become the standard of care in patients with high‐risk muscle‐invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).
Satoshi Katayama, Tatsushi Kawada, K. Mori et al.
· International journal of uro... · 1 citation